Join the Parkinson's Disease group to help and get support from people like you.
Parkinson's Disease News (Page 3)
Related terms: Parkinson's
Genetics Suggest Link Between ALS, Parkinson's Disease
MONDAY, Sept. 16, 2024 – People with rare genetic variants linked to degenerative brain disorders like Parkinson’s disease are at increased risk of developing ALS, a new study finds. Further, having ...
Upper GI Mucosal Damage Tied to Later Parkinson Disease Diagnosis
WEDNESDAY, Sept. 11, 2024 – A history of upper gastrointestinal mucosal damage (MD) is associated with a higher subsequent risk for developing Parkinson disease (PD), according to a study published...
No Link Found Between Migraines, Parkinson's Disease
FRIDAY, Aug. 23, 2024 – Women who suffer frequent migraines don’t have any increased risk of developing Parkinson’s disease, finds a new study that refutes earlier research. “These results are reass...
Migraine in Women Not Linked to Risk for Parkinson Disease
THURSDAY, Aug. 22, 2024 – Migraine is not associated with an increased risk for developing Parkinson disease (PD) among women, according to a study published online Aug. 21 in Neurology. Ricarda S....
Brain Implant Helps Tame Parkinson's for Easier Daily Living
MONDAY, Aug. 19, 2024 – A brain implant guided by AI could provide around-the-clock personalized care for people with Parkinson’s disease, a new study suggests. The implant uses AI to monitor a p...
FDA Approves Crexont (carbidopa and levodopa) Extended-Release Capsules for the Treatment of Parkinson’s Disease
BRIDGEWATER, N.J.--(BUSINESS WIRE) August 7, 2024 – Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has appro...
New Upright Scanner Tracks Brain Function While You Walk
FRIDAY, Aug. 9, 2024 – A wearable brain scanner could improve research into Parkinson’s disease, dementia and other debilitating disorders, new research shows. The brain scanner – called the A...
Dementia May Not Be as Common Among Parkinson's Patients as Thought
THURSDAY, Aug. 8, 2024 – Many people with Parkinson's disease may fear dementia as a common consequence of the disease. But new research suggests dementia is not inevitable with Parkinson's, and in...
Dementia May Occur Less Often, Develop Slower in Parkinson Disease Patients
WEDNESDAY, Aug. 7, 2024 – For patients with Parkinson disease (PD), dementia may occur less often or develop over a longer time period than previously thought, according to a study published online...
Fecal Microbiota Transplant No Aid for Parkinson Disease
FRIDAY, Aug. 2, 2024 – Fecal microbiota transplantation (FMT) is safe but does not offer clinically meaningful improvements for Parkinson disease (PD), according to a study published online July 29...
Risk of Parkinson Disease Heightened in People With Anxiety
MONDAY, July 22, 2024 – The risk of developing Parkinson disease (PD) is at least doubled in people with anxiety compared with those without, according to a study published in the July issue of...
Adamas Announces FDA Approval for Second Indication for Gocovri as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes
EMERYVILLE, Calif.--(BUSINESS WIRE)--Feb. 1, 2021-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people...
FDA Approves Kynmobi (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes
MARLBOROUGH, Mass.--(BUSINESS WIRE) May 21, 2020 --Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) has approved Kynmobi (apomorphine HCI)...
FDA Approves Ongentys (opicapone) as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes
SAN DIEGO – April 27, 2020 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Ongentys (opicapone) 25 mg and 50...
FDA Approves Nourianz (istradefylline) as an Add-On Drug to Treat Off Episodes in Adults with Parkinson’s Disease
TOKYO--(BUSINESS WIRE)-- August 28, 2019 – Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for Nourianz...